Chancellor, J V <br/><br/>
Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.  [electronic resource] 

 -  PharmacoEconomics  2001 
 - 59-75 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1170-7690 
<br/><br/><label>Standard No.: </label>10.2165/00019053-200119001-00005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anemia--chemically induced<br/>Anti-Inflammatory Agents, Non-Steroidal--adverse effects<br/>Anti-Ulcer Agents--economics<br/>Arthritis--drug therapy<br/>Celecoxib<br/>Clinical Trials as Topic<br/>Cost of Illness<br/>Cost-Benefit Analysis<br/>Cyclooxygenase Inhibitors--economics<br/>Decision Trees<br/>Drug Therapy, Combination<br/>Duodenal Ulcer--chemically induced<br/>Economics, Pharmaceutical<br/>Humans<br/>Probability<br/>Pyrazoles<br/>Sulfonamides--economics<br/>Switzerland